FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079762893> ?p ?o ?g. }

• W2079762893 abstract "It has become clear through epidemiological analysis that the incidence of cancers of the lung, liver, colon, and rectum are increasing in Japan every year. However, there have been few epidemiological analyses of nasopharyngeal carcinoma (NPC) in Japan. The aim of this study was to analyze the epidemiology and current incidence of NPC in the Chubu region of Japan during the period from 1996 to 2005.Takeshita et al. conducted a similar investigation in the Chubu region 10 years ago, and, as a result, this is a comparative study. The Chubu region is the central region of Japanese main island. We researched NPC patients treated in hospitals in each prefecture over a 10-year period (1996-2005) using a questionnaire.A total of 525 cases (male:385, female:134, unknown:6) were analyzed epidemiologically, histologically, serologically, and clinically in this study. The incidence per 10(5) population per year was 0.29. For the period of 1986-1995, the age-standardized incidence of NPC was 0.28 per 10(5) persons per year in Takeshita's report. There was no significant difference between the two periods. The ages of the patients ranged from 13 to 90 years. The mean age of was 55.2 years. On the basis of the World Health Organization (WHO) histological criteria, 36% of the patients were classified as WHO I, 27% as WHO II, and 37% as WHO III. Carcinoma was located in the posterosuperior region in 56%, lateral in 41%, and inferior in 3%. Tumor staging showed that 6% to belonged to stage I, 25% to stage II, 31% to stage III, and 38% to stage IV. A neck mass was present in 52% of the patients, ear symptoms in 48%, nasal symptoms in 27%, headaches in 10%, pharyngeal symptoms in 9%, ophthalmologic symptoms in 9%, and cranial neurological symptoms in 9%. The positive rates of serum titers of the antibodies to Epstein-Barr virus (EBV)-related antigens were calculated. The positive rate of anti-EBV-viral capsid antigen (VCA) immunoglobulin (Ig) G titers was 58.6%, that of anti-EBV-VCA IgA titers was 53.6%, and that of EBNA was 81%. The five-year survival rate for all patients was 67.6%, and that for those in stage I, II, III, and IV was 75%, 84%, 69%, and 53%, respectively. The five-year survival rate for stage IV was significantly lower than those for the other stages (P<0.05).The age-standardized annual incidence of NPC in our survey was 0.29 per 10(5) persons per year, being relatively low and stable." @default.
• W2079762893 created "2016-06-24" @default.
• W2079762893 creator A5010019607 @default.
• W2079762893 creator A5014718861 @default.
• W2079762893 creator A5018497343 @default.
• W2079762893 creator A5020927080 @default.
• W2079762893 creator A5021777107 @default.
• W2079762893 creator A5028354285 @default.
• W2079762893 creator A5028359272 @default.
• W2079762893 creator A5029691234 @default.
• W2079762893 creator A5042099238 @default.
• W2079762893 creator A5044097329 @default.
• W2079762893 creator A5044798660 @default.
• W2079762893 creator A5047844727 @default.
• W2079762893 creator A5050909345 @default.
• W2079762893 creator A5057446753 @default.
• W2079762893 creator A5059537540 @default.
• W2079762893 creator A5060464308 @default.
• W2079762893 creator A5060912740 @default.
• W2079762893 creator A5066409577 @default.
• W2079762893 creator A5068572982 @default.
• W2079762893 creator A5083456016 @default.
• W2079762893 creator A5090897933 @default.
• W2079762893 date "2011-04-01" @default.
• W2079762893 modified "2023-10-10" @default.
• W2079762893 title "Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005" @default.
• W2079762893 cites W1970625056 @default.
• W2079762893 cites W1989192190 @default.
• W2079762893 cites W1994373130 @default.
• W2079762893 cites W2017882478 @default.
• W2079762893 cites W2019638146 @default.
• W2079762893 cites W2026714592 @default.
• W2079762893 cites W2026867068 @default.
• W2079762893 cites W2036187493 @default.
• W2079762893 cites W2043037851 @default.
• W2079762893 cites W2051196762 @default.
• W2079762893 cites W2053849527 @default.
• W2079762893 cites W2055622515 @default.
• W2079762893 cites W2064651903 @default.
• W2079762893 cites W2079511879 @default.
• W2079762893 cites W2087595727 @default.
• W2079762893 cites W2089912579 @default.
• W2079762893 cites W2095755011 @default.
• W2079762893 cites W2095791535 @default.
• W2079762893 cites W2106871679 @default.
• W2079762893 cites W2111447964 @default.
• W2079762893 cites W2117102617 @default.
• W2079762893 cites W2117970070 @default.
• W2079762893 cites W2137750991 @default.
• W2079762893 cites W2170858457 @default.
• W2079762893 cites W4229818302 @default.
• W2079762893 cites W4254815359 @default.
• W2079762893 cites W2100263158 @default.
• W2079762893 doi "https://doi.org/10.1016/j.anl.2010.07.006" @default.
• W2079762893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20817430" @default.
• W2079762893 hasPublicationYear "2011" @default.
• W2079762893 type Work @default.
• W2079762893 sameAs 2079762893 @default.
• W2079762893 citedByCount "22" @default.
• W2079762893 countsByYear W20797628932012 @default.
• W2079762893 countsByYear W20797628932013 @default.
• W2079762893 countsByYear W20797628932014 @default.
• W2079762893 countsByYear W20797628932016 @default.
• W2079762893 countsByYear W20797628932017 @default.
• W2079762893 countsByYear W20797628932018 @default.
• W2079762893 countsByYear W20797628932019 @default.
• W2079762893 countsByYear W20797628932020 @default.
• W2079762893 countsByYear W20797628932021 @default.
• W2079762893 countsByYear W20797628932022 @default.
• W2079762893 crossrefType "journal-article" @default.
• W2079762893 hasAuthorship W2079762893A5010019607 @default.
• W2079762893 hasAuthorship W2079762893A5014718861 @default.
• W2079762893 hasAuthorship W2079762893A5018497343 @default.
• W2079762893 hasAuthorship W2079762893A5020927080 @default.
• W2079762893 hasAuthorship W2079762893A5021777107 @default.
• W2079762893 hasAuthorship W2079762893A5028354285 @default.
• W2079762893 hasAuthorship W2079762893A5028359272 @default.
• W2079762893 hasAuthorship W2079762893A5029691234 @default.
• W2079762893 hasAuthorship W2079762893A5042099238 @default.
• W2079762893 hasAuthorship W2079762893A5044097329 @default.
• W2079762893 hasAuthorship W2079762893A5044798660 @default.
• W2079762893 hasAuthorship W2079762893A5047844727 @default.
• W2079762893 hasAuthorship W2079762893A5050909345 @default.
• W2079762893 hasAuthorship W2079762893A5057446753 @default.
• W2079762893 hasAuthorship W2079762893A5059537540 @default.
• W2079762893 hasAuthorship W2079762893A5060464308 @default.
• W2079762893 hasAuthorship W2079762893A5060912740 @default.
• W2079762893 hasAuthorship W2079762893A5066409577 @default.
• W2079762893 hasAuthorship W2079762893A5068572982 @default.
• W2079762893 hasAuthorship W2079762893A5083456016 @default.
• W2079762893 hasAuthorship W2079762893A5090897933 @default.
• W2079762893 hasConcept C107130276 @default.
• W2079762893 hasConcept C120665830 @default.
• W2079762893 hasConcept C121332964 @default.
• W2079762893 hasConcept C126322002 @default.
• W2079762893 hasConcept C144024400 @default.
• W2079762893 hasConcept C149923435 @default.
• W2079762893 hasConcept C2778997737 @default.
• W2079762893 hasConcept C2781074409 @default.
• W2079762893 hasConcept C2908647359 @default.

• next